Oncology News | pharmaphorum

News

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.

News

Netcompany claims NHS contract to help digitise screening

Denmark's Netcompany has been awarded a five-year, £215m contract from NHS England to build the digital infrastructure for adult screening programmes.

News

Akeso's ivonescimab extends survival in PD-L1+ lung cancer

Akeso's PD-1xVEGF drug ivonescimab improves survival in another late-stage Chinese trial, ahead of a key international study readout later this year.

News

PMV cues up filing for first p53-directed cancer therapy

PMV is preparing to file for approval of its first-in-class oral p53 protein reactivator, rezatopopt, for ovarian cancer in the first quarter of 2027.

News